If you made any changes in Pure these will be visible here soon.

Research Output 2006 2019

Filter
Comment / Debate
2019

Correction: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia (Blood Cancer Journal, (2018), 8, 8, (68), 10.1038/s41408-018-0103-6)

Marquis, M., Beaubois, C., Lavallée, V. P., Abrahamowicz, M., Danieli, C., Lemieux, S., Ahmad, I., Wei, A., Ting, S. B., Fleming, S., Schwarer, A., Grimwade, D., Grey, W., Hills, R. K., Vyas, P., Russell, N., Sauvageau, G. & Hébert, J., 1 Mar 2019, In : Blood Cancer Journal. 9, 3, 1 p., 28.

Research output: Contribution to journalComment / DebateOtherpeer-review

Open Access
2017

Corrigendum to “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study” [Leuk. Res. 50 (Nov) (2016) 123–131. PubMed PMID: 27736729](S0145212616301989)(10.1016/j.leukres.2016.09.012)

Swords, R. T., Greenberg, P. L., Wei, A. H., Durrant, S., Advani, A. S., Hertzberg, M. S., Lewis, I. D., Rivera, G., Gratzinger, D., Fan, A. C., Felsher, D. W., Cortes, J. E., Watts, J. M., Yarranton, G. T., Walling, J. M. & Lancet, J. E., 1 Aug 2017, In : Leukemia Research. 59, 1 p.

Research output: Contribution to journalComment / DebateOtherpeer-review

2016

Correction: Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics (Cancer Cell (2016) 30(3) (499–500) (S1535610816000350) (10.1016/j.ccell.2016.01.006))

Lalaoui, N., Hänggi, K., Brumatti, G., Chau, D., Nguyen, N. Y. N., Vasilikos, L., Spilgies, L. M., Heckmann, D. A., Ma, C., Ghisi, M., Salmon, J. M., Matthews, G. M., de Valle, E., Moujalled, D. M., Menon, M. B., Spall, S. K., Glaser, S. P., Richmond, J., Lock, R. B., Condon, S. M. & 10 othersGugasyan, R., Gaestel, M., Guthridge, M., Johnstone, R. W., Munoz, L., Wei, A., Ekert, P. G., Vaux, D. L., Wong, W. W. L. & Silke, J., 12 Sep 2016, In : Cancer Cell. 30, 3, p. 499-500 2 p.

Research output: Contribution to journalComment / DebateOtherpeer-review

2014

Erratum: Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia (Blood Cancer Journal (2014) 4 (e237) DOI: 10.1038/bcj.2014.59)

Cummins, K. D., Jane, S. M., Ninkovic, S., Bazargan, A., Filshie, R. J. A., Sutrave, G., Hertzberg, M., Scott, A., Lane, S., Yannakou, C. K., Ritchie, P. D., D'Rozario, J., Black, J., Bavishi, K. & Wei, A., 1 Jan 2014, In : Blood Cancer Journal. 4, 9, e246.

Research output: Contribution to journalComment / DebateOtherpeer-review

2008

Bortezomib: Putting mantle cell lymphoma on death row

Wei, A. H. & Roberts, A. W., 1 Apr 2008, In : Leukemia and Lymphoma. 49, 4, p. 657-658 2 p.

Research output: Contribution to journalComment / DebateOtherpeer-review